PCR London Valves 2025

18 Nov 2025

TAVI

A new era for aortic regurgitation: how new guidelines and dedicated devices for AR will redefine treatment

Sponsored by JenaValve Technology

Spokesperson: M. Gilard

Discussants: M. Adam, H. Treede

Summary

This session examines the evolving treatment landscape for aortic regurgitation (AR) in light of new ESC guidelines and dedicated devices such as the JenaValve Trilogy System. It provides an in-depth look at refined diagnosis, optimized treatment strategies, and presents real-world data and clinical cases that highlight the commercial performance and efficacy of the Trilogy System in Europe.

Learning Objectives

To understand how the new ESC guidelines will refine the diagnosis and optimise the treatment of aortic regurgitation (AR) and help improve patient care of this undertreated disease
To learn about and observe cases featuring the JenaValve Trilogy System, the only CE Mark-approved device for treating both severe aortic regurgitation and aortic stenosis
To see real-world, never before presented data on the Trilogy System and the commercial performance in Europe

Welcome and session objectives

Download presentation